ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.88
-0.44%
Dow Jones
40,211.72
0.53%
Gold vs US Dollar
2,435.27
0.54%
Brent Oil
83.69
-0.77%
Bitcoin
62,999.74
-2.86%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. (MM) (IDIX)

  7. (MM) (IDIX) News

(MM) (IDIX)

(MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IDIX
DateTimeSourceHeadlineSymbolCompany
08/02/200613:30PR Newswire (US)Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference and 2006 Citigroup Healthcare ConferenceNASDAQ:IDIX(MM)
07/02/200613:00PR Newswire (US)Idenix and Novartis Seek European Approval of Telbivudine for the Treatment of Patients with Chronic Hepatitis BNASDAQ:IDIX(MM)
23/01/200613:30PR Newswire (US)Idenix Pharmaceuticals, Inc. Announces Appointment of Susan Koppy as Senior Vice President, Business and Corporate DevelopmentNASDAQ:IDIX(MM)
17/01/200623:30PR Newswire (US)American Stock Exchange to Trade Options on Fourteen SecuritiesNASDAQ:IDIX
09/01/200613:03PR Newswire (US)Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase IIb Clinical Trial Evaluating Valopicitabine (NM283) Combined wNASDAQ:IDIX(MM)
05/01/200617:14PR Newswire (US)Idenix Pharmaceuticals to Present at 24th Annual JPMorgan Healthcare ConferenceNASDAQ:IDIX(MM)
03/01/200613:00PR Newswire (US)Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the TreNASDAQ:IDIX(MM)
03/01/200613:00PR Newswire (US)Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for The TreNASDAQ:IDIX(MM)
14/12/200514:56PR Newswire (US)Partial 24-Week Data Demonstrate Valopicitabine (NM283) Combined with Pegylated Interferon Continues to Produce Greater Viral SuNASDAQ:IDIX(MM)
02/12/200517:02PR Newswire (US)Idenix Provides Update on Clinical Development Program for Valopicitabine (NM283) for the Treatment of Hepatitis CNASDAQ:IDIX(MM)
28/11/200513:30PR Newswire (US)Idenix Announces Exercise of Underwriters' Over-Allotment Option and Completion of SaleNASDAQ:IDIX(MM)
11/11/200516:00PR Newswire (US)Valopicitabine (NM283) Combined with Pegylated Interferon Demonstrated Significantly Greater Suppression of Hepatitis C Virus (HNASDAQ:IDIX(MM)
08/11/200513:30PR Newswire (US)Idenix Pharmaceuticals to Present at Credit Suisse First Boston's Healthcare ConferenceNASDAQ:IDIX(MM)
03/11/200521:05PR Newswire (US)Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial ResultsNASDAQ:IDIX(MM)
28/10/200514:00PR Newswire (US)Idenix to Host Conference Call Discussing Third Quarter 2005 Financial Results on November 3, 2005 at 4:30 p.m. ETNASDAQ:IDIX(MM)
26/10/200514:01PR Newswire (US)Idenix Announces Pricing of Public Offering of Common StockNASDAQ:IDIX(MM)
24/10/200523:08PR Newswire (US)Idenix Announces Public Offering of Common StockNASDAQ:IDIX(MM)
03/10/200518:03PR Newswire (US)Idenix Announces Data Presentations at the 2005 56th Annual Meeting of the American Association for the Study of Liver DiseasesNASDAQ:IDIX(MM)
01/09/200514:30PR Newswire (US)Idenix Pharmaceuticals to Present at Three Upcoming ConferencesNASDAQ:IDIX(MM)
28/07/200522:02PR Newswire (US)Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial ResultsNASDAQ:IDIX(MM)
28/07/200522:02PR Newswire (US)Telbivudine Achieves Primary Endpoint in Phase III GLOBE Trial, Largest Ever Registration Trial in Hepatitis BNASDAQ:IDIX(MM)
18/07/200514:30PR Newswire (US)Idenix to Webcast Conference Call Discussing Second Quarter 2005 Financial ResultsNASDAQ:IDIX(MM)
07/06/200522:15PR Newswire (US)Idenix Pharmaceuticals to Present at the Goldman Sachs Global Healthcare ConferenceNASDAQ:IDIX(MM)
07/06/200515:25PR Newswire (US)Shareholders Approve Proxy Proposals at Idenix Pharmaceuticals Annual MeetingNASDAQ:IDIX(MM)
31/05/200514:30PR Newswire (US)Idenix Pharmaceuticals Completes Enrollment of Valopicitabine (NM283) Phase IIb Trial in Treatment Refractory Hepatitis C GenotyNASDAQ:IDIX(MM)
18/05/200514:30PR Newswire (US)Pamela Thomas-Graham, Chairman of CNBC, Appointed to Board of Directors of Idenix PharmaceuticalsNASDAQ:IDIX(MM)
16/05/200522:05PR Newswire (US)Positive Two-Year Data for Telbivudine for the Treatment of Chronic Hepatitis B Presented at 2005 Digestive Disease Week (DDW) MNASDAQ:IDIX(MM)
16/05/200514:30PR Newswire (US)Idenix Pharmaceuticals Selected to Join the NASDAQ Biotechnology IndexNASDAQ:IDIX(MM)
14/05/200500:35PR Newswire (US)Semi-Annual Changes to the NASDAQ Biotechnology IndexNASDAQ:IDIX(MM)
10/05/200514:30PR Newswire (US)Idenix Pharmaceuticals to Present at BioEquity Europe 2005, The Needham & Company Fourth Annual Biotechnology Conference and TheNASDAQ:IDIX(MM)
 Showing the most relevant articles for your search:NASDAQ:IDIX

Your Recent History

LSE
CPX
Cap-xx
LSE
GDR
Genedrive
LSE
OCDO
Ocado
LSE
ITM
Itm Power
LSE
BOO
Boohoo
LSE
BARC
Barclays
LSE
ENET
Ethernity Networks
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
TRT
Transense Technologies
LSE
CPI
Capita
LSE
PRU
Prudential
LSE
SYME
Supply@me Capital
LSE
IOF
Iofina
LSE
CGH
Chaarat Gold
LSE
JSE
Jadestone Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved